SCHEMBL19636124

SCHEMBL19636124

NC(=O)c1c(-c2ccc(Oc3ccc(Cl)cn3)cc2)nn(C2CCC3(CC3)N(C(=O)/C=C/CO)C2)c1N

nearest known ligand 0.75

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
BTK Q06187 20/20 0.75
EGFR P00533 10/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20985194 1.00 BTK (0.75) BTKEGFR
SCHEMBL19636163 0.91 BTK (0.74) BTKEGFR
SCHEMBL19636164 0.91 BTK (0.74) BTKEGFR
SCHEMBL19636126 0.91 BTK (0.74) BTKEGFR
SCHEMBL19635642 0.86 BTK (0.58) BTKEGFR
SCHEMBL19635646 0.86 BTK (0.58) BTKEGFR
SCHEMBL19635644 0.86 BTK (0.58) BTKEGFR
SCHEMBL15670329 0.85 BTK (1.00) BTKEGFR
SCHEMBL17173976 0.85 BTK (1.00) BTKEGFR
SCHEMBL15670327 0.85 BTK (1.00) BTKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3459940-B1 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF SUZHOU SINOVENT PHARMACEUTICALS CO LTD (CN) 2022-07-20 EP disclosed
US-10882843-B2 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2021-01-05 US disclosed
US-10882843-B2 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2021-01-05 US disclosed
US-20190152952-A1 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF Evopoint Biosciences Co., Ltd. (CN) 2019-05-23 US disclosed
US-20190152952-A1 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF Evopoint Biosciences Co., Ltd. (CN) 2019-05-23 US disclosed
EP-3459940-A1 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF Zhejiang Yukon Pharma Co., Ltd. (CN) 2019-03-27 EP disclosed
WO-2017198050-A1 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF 浙江予川医药科技有限公司 2017-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10882843-B2 5-aminopyrazole carboxamide derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof BTK, SYK, LCK BTK 1/4885EGFR 607/4885
US-20190152952-A1 5-AMINOPYRAZOLE CARBOXAMIDE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF BTK, SYK, LCK BTK 1/4885EGFR 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.